Literature DB >> 11181375

Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.

D N Gilbert1, S J Kohlhepp, K A Slama, G Grunkemeier, G Lewis, R J Dworkin, S E Slaughter, J E Leggett.   

Abstract

The phenotypic resistance of selected organisms to ciprofloxacin, levofloxacin, and trovafloxacin was defined as a MIC of > or =4 microg/ml. The dynamics of resistance were studied after single and sequential drug exposures: clinical isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA), Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, and Pseudomonas aeruginosa were utilized. After a single 48-h exposure of a large inoculum to four times the initial MIC for the organism, the frequency of selection of resistant mutants of MSSA was greater for trovafloxacin than levofloxacin (P = 0.008); for E. cloacae, the frequency was highest for ciprofloxacin and lowest for levofloxacin and trovafloxacin; for S. marcescens, the frequency was highest for trovafloxacin and lowest for ciprofloxacin (P = 0.003). The results of serial passage experiments were analyzed both by the Kaplan-Meier product-limited method as well as by analysis of variance of mean inhibitory values. By both methods, MSSA and MRSA expressed mutants resistant to ciprofloxacin after fewer passages than were required for either levofloxacin or trovafloxacin. For the aerobic gram-negative bacilli, two general patterns emerged. Mutants resistant to trovafloxacin appeared sooner and reached higher mean MICs than did mutants resistant to levofloxacin or ciprofloxacin. Mutants resistant to ciprofloxacin appeared later and reached mean MICs lower than the MICs of the other two drugs studied. Even though individual strain variation occurred, the mean MICs were reproduced when the serial passage experiment was repeated using an identical panel of E. coli isolates. In summary, the dynamic selection of fluoroquinolone-resistant bacteria can be demonstrated in experiments that employ serial passage of bacteria in vitro.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181375      PMCID: PMC90388          DOI: 10.1128/AAC.45.3.883-892.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Ciprofloxacin-resistant Salmonella typhi and treatment failure.

Authors:  E J Threlfall; L R Ward; J A Skinner; H R Smith; S Lacey
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Emergence and dissemination of quinolone-resistant Escherichia coli in the community.

Authors:  J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.

Authors:  L R Peterson; J N Quick; B Jensen; S Homann; S Johnson; J Tenquist; C Shanholtzer; R A Petzel; L Sinn; D N Gerding
Journal:  Arch Intern Med       Date:  1990-10

4.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.

Authors:  M E Mulligan; P J Ruane; L Johnston; P Wong; J P Wheelock; K MacDonald; J F Reinhardt; C C Johnson; B Statner; I Blomquist
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 8.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 9.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

10.  In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.

Authors:  W Mandell; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more
  16 in total

1.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Philip Chung; Patrick J McNamara; William B Titlow; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Fluoroquinolone-resistant uncomplicated urinary tract infections, Chinese herbal medicine may provide help.

Authors:  Yanqing Tong; Yue Jing; Dongkai Zhao; Liping Zhang; Shiming Zeng
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

Review 7.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

8.  The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported.

Authors:  Maureen K Bolon; Sharon B Wright; Howard S Gold; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei.

Authors:  Y Y Chan; T M C Tan; Y M Ong; K L Chua
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.